Active, not recruiting
The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer
NCT06115499· Phase 2/3· Alliance for Clinical Trials in Oncology· Source
Recruiting
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
NCT05806515· Phase 2· SWOG Cancer Research Network· Source
Contact: Shahzad Siddique (principal investigator)
Active, not recruiting
Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma
NCT05694871· Phase 2· Alliance for Clinical Trials in Oncology· Source
Recruiting
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
NCT05677490· Phase 3· Alliance for Clinical Trials in Oncology· Source
Contact: Aishwarya Vijendran
Active, not recruiting
Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)
NCT05241860· Phase 2· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy
NCT04637594· Phase 3· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
NCT04455750· Phase 3· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring
NCT04597359· Phase 2· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
NCT04579224· Phase 3· National Cancer Institute (NCI)· Source
Recruiting
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
NCT04858334· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
NCT04739800· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
NCT04647916· Phase 2· SWOG Cancer Research Network· Source
Active, not recruiting
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
NCT04625647· Phase 2· SWOG Cancer Research Network· Source
Recruiting
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
NCT04269902· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer
NCT04559139· Phase 2/3· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations
NCT04548752· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
NCT04462406· Phase 2· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden
NCT04145115· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients
NCT04444921· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread
NCT04233866· Phase 2· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker
NCT04334941· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer
NCT04310007· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer
NCT04137107· Phase 2/3· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
NCI COVID-19 in Cancer Patients, NCCAPS Study
NCT04387656· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body
NCT04248452· Phase 3· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
NCT04092283· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver
NCT04175912· Phase 2· National Cancer Institute (NCI)· Source
Recruiting
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
NCT04242095· Alliance for Clinical Trials in Oncology· Source
Contact: David Kozono, MD, PhD
Active, not recruiting
Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
NCT04166318· Phase 2· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
NCT04068103· Phase 2/3· NRG Oncology· Source
Active, not recruiting
A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
NCT04115631· Phase 2· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
NCT04094688· Phase 3· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
NCT03984448· Phase 2/3· National Cancer Institute (NCI)· Source
Active, not recruiting
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT04095364· Phase 3· NRG Oncology· Source
Active, not recruiting
Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer
NCT03811015· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
NCT04071457· Phase 3· SWOG Cancer Research Network· Source
Active, not recruiting
Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
NCT03516279· Phase 2· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
NCT03793166· Phase 3· National Cancer Institute (NCI)· Source
Recruiting
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
NCT03866382· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer
NCT03348631· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer
NCT03793179· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma
NCT03698019· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia
NCT03701282· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
NCT03737981· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)
NCT03595124· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations
NCT03609216· Phase 2· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia
NCT03654768· Phase 2· SWOG Cancer Research Network· Source
Active, not recruiting
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
NCT03660826· Phase 2· National Cancer Institute (NCI)· Source
Recruiting
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NCT03723928· SWOG Cancer Research Network· Source
Contact: Shahzad Siddique (principal investigator)
Active, not recruiting
Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
NCT03228537· Phase 1· National Cancer Institute (NCI)· Source
Showing 50 of 87.